Structured Review

Horizon Discovery sirna experiments gene expression
Cisplatin induces intrinsic and ROS dependent apoptosis. a Division rate was determined by counting cells on 4 consecutive days. b , c Viable (Annexin V negative/PI negative) cells after co-incubation with b 2 mM Glutathion or c 50 µM zVAD-fmk and 10 µM cisplatin for 48 h. ( d , bottom) Western blot analysis of <t>BAX</t> and BAK expression in cells transfected with <t>siRNA</t> targeting BAX and BAK or control siRNA and ( d , top) flow cytometric analysis of viability (Annexin V negative/PI negative) after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD from at least three independent experiments
Sirna Experiments Gene Expression, supplied by Horizon Discovery, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sirna experiments gene expression/product/Horizon Discovery
Average 93 stars, based on 1 article reviews
Price from $9.99 to $1999.99
sirna experiments gene expression - by Bioz Stars, 2020-08
93/100 stars

Related Products / Commonly Used Together

tfam
sigenome smartpool sirna
bax
pgc1α
ucp2
bak

Images

1) Product Images from "Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells"

Article Title: Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells

Journal: Cell Death & Disease

doi: 10.1038/s41419-019-2081-4

Cisplatin induces intrinsic and ROS dependent apoptosis. a Division rate was determined by counting cells on 4 consecutive days. b , c Viable (Annexin V negative/PI negative) cells after co-incubation with b 2 mM Glutathion or c 50 µM zVAD-fmk and 10 µM cisplatin for 48 h. ( d , bottom) Western blot analysis of BAX and BAK expression in cells transfected with siRNA targeting BAX and BAK or control siRNA and ( d , top) flow cytometric analysis of viability (Annexin V negative/PI negative) after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD from at least three independent experiments
Figure Legend Snippet: Cisplatin induces intrinsic and ROS dependent apoptosis. a Division rate was determined by counting cells on 4 consecutive days. b , c Viable (Annexin V negative/PI negative) cells after co-incubation with b 2 mM Glutathion or c 50 µM zVAD-fmk and 10 µM cisplatin for 48 h. ( d , bottom) Western blot analysis of BAX and BAK expression in cells transfected with siRNA targeting BAX and BAK or control siRNA and ( d , top) flow cytometric analysis of viability (Annexin V negative/PI negative) after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD from at least three independent experiments

Techniques Used: Incubation, Western Blot, Expressing, Transfection, Flow Cytometry

Reduction of mtROS enhances survival after cisplatin treatment. a – c Flow cytometric analysis of OVCAR-3 and OVCAR-4 after co-treatment with ATP synthase inhibitor Oligomycin A (5 µM) and 10 µM cisplatin for 48 h. a Oligomycin A reduces cisplatin mediated mtROS induction (MitoSOX red) while b mitochondrial content (Mitotracker Green) is unaffected. c Oligomycin A increases viability (Annexin V negative/PI negative) after cisplatin incubation. d Western blot analysis of OVCAR-3 and OVCAR-8 cells after treatment with 10 µM cisplatin for 48 h shows increased TFAM protein expression. e – g siRNA mediated knockdown of PGC1α in OVCAR-4. e Expression of PGC1α (top) and TFAM (bottom) are decreased in transfected OVCAR-4 cells. f Flow cytometric analysis shows decreased mtROS induction (MitoSox red) in PGC1α silenced cells after treatment with 10 µM cisplatin for 48 h. g Flow cytometric analysis of cell viability (Annexin V negative/PI negative) reveals PGCA1 α knockdown mediated enhanced survival after treatment with 10 µM cisplatin for 48 h. ( h , left) siRNA mediated knockdown of TFAM in OVCAR-4 cells ( h , right) is associated with enhanced viability (Annexin V negative/PI negative) in a flow cytometric analysis after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD or a representative experiment from at least three independent experiments
Figure Legend Snippet: Reduction of mtROS enhances survival after cisplatin treatment. a – c Flow cytometric analysis of OVCAR-3 and OVCAR-4 after co-treatment with ATP synthase inhibitor Oligomycin A (5 µM) and 10 µM cisplatin for 48 h. a Oligomycin A reduces cisplatin mediated mtROS induction (MitoSOX red) while b mitochondrial content (Mitotracker Green) is unaffected. c Oligomycin A increases viability (Annexin V negative/PI negative) after cisplatin incubation. d Western blot analysis of OVCAR-3 and OVCAR-8 cells after treatment with 10 µM cisplatin for 48 h shows increased TFAM protein expression. e – g siRNA mediated knockdown of PGC1α in OVCAR-4. e Expression of PGC1α (top) and TFAM (bottom) are decreased in transfected OVCAR-4 cells. f Flow cytometric analysis shows decreased mtROS induction (MitoSox red) in PGC1α silenced cells after treatment with 10 µM cisplatin for 48 h. g Flow cytometric analysis of cell viability (Annexin V negative/PI negative) reveals PGCA1 α knockdown mediated enhanced survival after treatment with 10 µM cisplatin for 48 h. ( h , left) siRNA mediated knockdown of TFAM in OVCAR-4 cells ( h , right) is associated with enhanced viability (Annexin V negative/PI negative) in a flow cytometric analysis after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD or a representative experiment from at least three independent experiments

Techniques Used: Flow Cytometry, Incubation, Western Blot, Expressing, Transfection

Related Articles

Expressing:

Article Title: Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells
Article Snippet: .. siRNA experiments Gene expression of BAX, BAK, PGC1α, TFAM, or UCP2 was silenced using siGENOME SMARTpool siRNA (Horizon Discovery Ltd, Cambridge, GB). .. Control cells were transfected with siGenome Non-Targeting siRNA #1.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Horizon Discovery sirna experiments gene expression
    Cisplatin induces intrinsic and ROS dependent apoptosis. a Division rate was determined by counting cells on 4 consecutive days. b , c Viable (Annexin V negative/PI negative) cells after co-incubation with b 2 mM Glutathion or c 50 µM zVAD-fmk and 10 µM cisplatin for 48 h. ( d , bottom) Western blot analysis of <t>BAX</t> and BAK expression in cells transfected with <t>siRNA</t> targeting BAX and BAK or control siRNA and ( d , top) flow cytometric analysis of viability (Annexin V negative/PI negative) after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD from at least three independent experiments
    Sirna Experiments Gene Expression, supplied by Horizon Discovery, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sirna experiments gene expression/product/Horizon Discovery
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sirna experiments gene expression - by Bioz Stars, 2020-08
    93/100 stars
      Buy from Supplier

    Image Search Results


    Cisplatin induces intrinsic and ROS dependent apoptosis. a Division rate was determined by counting cells on 4 consecutive days. b , c Viable (Annexin V negative/PI negative) cells after co-incubation with b 2 mM Glutathion or c 50 µM zVAD-fmk and 10 µM cisplatin for 48 h. ( d , bottom) Western blot analysis of BAX and BAK expression in cells transfected with siRNA targeting BAX and BAK or control siRNA and ( d , top) flow cytometric analysis of viability (Annexin V negative/PI negative) after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD from at least three independent experiments

    Journal: Cell Death & Disease

    Article Title: Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells

    doi: 10.1038/s41419-019-2081-4

    Figure Lengend Snippet: Cisplatin induces intrinsic and ROS dependent apoptosis. a Division rate was determined by counting cells on 4 consecutive days. b , c Viable (Annexin V negative/PI negative) cells after co-incubation with b 2 mM Glutathion or c 50 µM zVAD-fmk and 10 µM cisplatin for 48 h. ( d , bottom) Western blot analysis of BAX and BAK expression in cells transfected with siRNA targeting BAX and BAK or control siRNA and ( d , top) flow cytometric analysis of viability (Annexin V negative/PI negative) after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD from at least three independent experiments

    Article Snippet: siRNA experiments Gene expression of BAX, BAK, PGC1α, TFAM, or UCP2 was silenced using siGENOME SMARTpool siRNA (Horizon Discovery Ltd, Cambridge, GB).

    Techniques: Incubation, Western Blot, Expressing, Transfection, Flow Cytometry

    Reduction of mtROS enhances survival after cisplatin treatment. a – c Flow cytometric analysis of OVCAR-3 and OVCAR-4 after co-treatment with ATP synthase inhibitor Oligomycin A (5 µM) and 10 µM cisplatin for 48 h. a Oligomycin A reduces cisplatin mediated mtROS induction (MitoSOX red) while b mitochondrial content (Mitotracker Green) is unaffected. c Oligomycin A increases viability (Annexin V negative/PI negative) after cisplatin incubation. d Western blot analysis of OVCAR-3 and OVCAR-8 cells after treatment with 10 µM cisplatin for 48 h shows increased TFAM protein expression. e – g siRNA mediated knockdown of PGC1α in OVCAR-4. e Expression of PGC1α (top) and TFAM (bottom) are decreased in transfected OVCAR-4 cells. f Flow cytometric analysis shows decreased mtROS induction (MitoSox red) in PGC1α silenced cells after treatment with 10 µM cisplatin for 48 h. g Flow cytometric analysis of cell viability (Annexin V negative/PI negative) reveals PGCA1 α knockdown mediated enhanced survival after treatment with 10 µM cisplatin for 48 h. ( h , left) siRNA mediated knockdown of TFAM in OVCAR-4 cells ( h , right) is associated with enhanced viability (Annexin V negative/PI negative) in a flow cytometric analysis after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD or a representative experiment from at least three independent experiments

    Journal: Cell Death & Disease

    Article Title: Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells

    doi: 10.1038/s41419-019-2081-4

    Figure Lengend Snippet: Reduction of mtROS enhances survival after cisplatin treatment. a – c Flow cytometric analysis of OVCAR-3 and OVCAR-4 after co-treatment with ATP synthase inhibitor Oligomycin A (5 µM) and 10 µM cisplatin for 48 h. a Oligomycin A reduces cisplatin mediated mtROS induction (MitoSOX red) while b mitochondrial content (Mitotracker Green) is unaffected. c Oligomycin A increases viability (Annexin V negative/PI negative) after cisplatin incubation. d Western blot analysis of OVCAR-3 and OVCAR-8 cells after treatment with 10 µM cisplatin for 48 h shows increased TFAM protein expression. e – g siRNA mediated knockdown of PGC1α in OVCAR-4. e Expression of PGC1α (top) and TFAM (bottom) are decreased in transfected OVCAR-4 cells. f Flow cytometric analysis shows decreased mtROS induction (MitoSox red) in PGC1α silenced cells after treatment with 10 µM cisplatin for 48 h. g Flow cytometric analysis of cell viability (Annexin V negative/PI negative) reveals PGCA1 α knockdown mediated enhanced survival after treatment with 10 µM cisplatin for 48 h. ( h , left) siRNA mediated knockdown of TFAM in OVCAR-4 cells ( h , right) is associated with enhanced viability (Annexin V negative/PI negative) in a flow cytometric analysis after treatment with 10 µM cisplatin for 48 h. Data represent means ± SD or a representative experiment from at least three independent experiments

    Article Snippet: siRNA experiments Gene expression of BAX, BAK, PGC1α, TFAM, or UCP2 was silenced using siGENOME SMARTpool siRNA (Horizon Discovery Ltd, Cambridge, GB).

    Techniques: Flow Cytometry, Incubation, Western Blot, Expressing, Transfection